Kotak Asset Managers invests ₹20 cr in Cellogen Therapeutics

Kotak Alternate Asset Managers on Monday said it has invested ₹20 crore in NATCO Pharma-backed Cellogen Therapeutics.

The investment has been made through Kotak Life Sciences Fund I (KLSF-I), which typically invests in early- to growth-stage life sciences and healthcare businesses. Cellogen will use the funds to advance its CAR’T clinical programmes, expand its gene therapy pipeline, and strengthen manufacturing, a release said.

Damroo raises ₹5 crore from Hindustan Times Music streaming platform Damroo on Monday announced a ₹5 crore fund raise from Hindustan Times.

The funding will support the platform’s efforts to scale artist development, audience growth, monetisation, and industry support initiatives, according to a statement.

Also Read: Triveni Turbine declares 200% dividend as Q4 net profit and revenue rise